151 related articles for article (PubMed ID: 11269647)
1. Implications of oncogenomics for cancer research and clinical oncology.
Herrmann JL; Rastelli L; Burgess CE; Fernandez EE; Rothberg BE; Rothberg JM; Shimkets RA
Cancer J; 2001; 7(1):40-51. PubMed ID: 11269647
[TBL] [Abstract][Full Text] [Related]
2. Genetic cancer syndromes and large-scale gene expression analysis: applications in surgical oncology.
Liefers GJ; Tollenaar RA; Nakamura Y; van de Velde CJ
Eur J Surg Oncol; 2001 Jun; 27(4):343-8. PubMed ID: 11417977
[TBL] [Abstract][Full Text] [Related]
3. Cancer biology: signatures guide drug choice.
Downward J
Nature; 2006 Jan; 439(7074):274-5. PubMed ID: 16421553
[No Abstract] [Full Text] [Related]
4. Novel strategies for therapeutic design in molecular oncology using gene expression profiles.
Ricci MS; el-Deiry WS
Curr Opin Mol Ther; 2000 Dec; 2(6):682-90. PubMed ID: 11249746
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. [Tissue array technology for translational research. From gene discovery to application].
Kim WH
Exp Mol Med; 2001 Apr; 33(1 Suppl):135-48. PubMed ID: 11708321
[TBL] [Abstract][Full Text] [Related]
7. The genomics revolution and radiotherapy.
West CM; Elliott RM; Burnet NG
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):470-80. PubMed ID: 17419040
[TBL] [Abstract][Full Text] [Related]
8. [Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers].
Nishiyama M
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1902-7. PubMed ID: 16282724
[TBL] [Abstract][Full Text] [Related]
9. Application of expression genomics for predicting treatment response in cancer.
Chin KV; Alabanza L; Fujii K; Kudoh K; Kita T; Kikuchi Y; Selvanayagam ZE; Wong YF; Lin Y; Shih WC
Ann N Y Acad Sci; 2005 Nov; 1058():186-95. PubMed ID: 16394136
[TBL] [Abstract][Full Text] [Related]
10. Cancer genomics: promises and complexities.
Zhang W; Labordé PM; Coombes KR; Berry DA; Hamilton SR
Clin Cancer Res; 2001 Aug; 7(8):2159-67. PubMed ID: 11489789
[TBL] [Abstract][Full Text] [Related]
11. Gene expression-driven diagnostics and pharmacogenomics in cancer.
Wang Y
Curr Opin Mol Ther; 2005 Jun; 7(3):246-50. PubMed ID: 15977422
[TBL] [Abstract][Full Text] [Related]
12. In silico identification of breast cancer genes by combined multiple high throughput analyses.
Shen D; He J; Chang HR
Int J Mol Med; 2005 Feb; 15(2):205-12. PubMed ID: 15647832
[TBL] [Abstract][Full Text] [Related]
13. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
Glinsky GV
J Clin Oncol; 2008 Jun; 26(17):2846-53. PubMed ID: 18539963
[TBL] [Abstract][Full Text] [Related]
14. National Oncology Forum: perspectives for the year 2000.
DeVita VT; Bleickardt EW
Cancer J; 2001; 7 Suppl 1():S2-13. PubMed ID: 11504281
[TBL] [Abstract][Full Text] [Related]
15. [Individuated molecular target chemotherapy].
Yamamoto W; Endo W; Sato A; Matsukawa M
Nihon Rinsho; 2002 Jan; 60(1):168-73. PubMed ID: 11808329
[TBL] [Abstract][Full Text] [Related]
16. The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine.
Foekens JA; Wang Y; Martens JW; Berns EM; Klijn JG
Drug Discov Today; 2008 Jun; 13(11-12):481-7. PubMed ID: 18549973
[TBL] [Abstract][Full Text] [Related]
17. SAGE and related approaches for cancer target identification.
Porter D; Yao J; Polyak K
Drug Discov Today; 2006 Feb; 11(3-4):110-8. PubMed ID: 16533708
[TBL] [Abstract][Full Text] [Related]
18. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics.
Chen W; Salto-Tellez M; Palanisamy N; Ganesan K; Hou Q; Tan LK; Sii LH; Ito K; Tan B; Wu J; Tay A; Tan KC; Ang E; Tan BK; Tan PH; Ito Y; Tan P
Genes Chromosomes Cancer; 2007 Mar; 46(3):288-301. PubMed ID: 17171680
[TBL] [Abstract][Full Text] [Related]
19. The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
Ferrer-Alcón M; Arteta D; Guerrero MJ; Fernandez-Orth D; Simón L; Martinez A
Toxicol Lett; 2009 Apr; 186(1):45-51. PubMed ID: 19022361
[TBL] [Abstract][Full Text] [Related]
20. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
